Company Overview
Sutro Biopharma, Inc. operates within the healthcare sector as a specialized biotechnology company focused on oncology. The firm develops site-specific and novel-format antibody drug conjugates (ADCs) that enable its proprietary integrated cell-free protein synthesis platform, XpressCF, as well as its site-specific conjugation platform, XpressCF+. As of the latest data, the company holds a market capitalization of $386.56M, which reflects its valuation as a mid-sized entity in the biotechnology landscape. Despite the absence of specific employee count data in current filings, the company has generated annual revenue of $102.48M over the trailing twelve months. This market capitalization and revenue profile indicate that Sutro Biopharma is an established but still developing player, likely reliant on future clinical success to expand its scale and reduce its dependence on external capital markets.
Financial Health
The company reported revenue of $102.48M for the trailing twelve months, yet it simultaneously recorded a net income of $-191,086,000 and an EBITDA of $-97,628,000. The substantial gap between the positive revenue figure and the significantly negative net income reveals a cost structure characterized by high operating expenses that far exceed current sales, a common trait in early-stage biotechnology firms. Free cash flow stands at $-123,992,000, indicating that the company is currently burning cash rather than generating liquidity from its operations. This negative cash flow implies limited financial flexibility for discretionary spending, necessitating ongoing access to capital markets or existing reserves to fund research and development activities. Gross margin is reported at 100.0%, while operating margin sits at -289.0% and profit margin at -186.5%. The 100.0% gross margin suggests that the cost of goods sold is effectively zero relative to revenue, yet the deeply negative operating and profit margins confirm that selling, general, and administrative costs are overwhelming any gross profit generation. Total cash on hand is $141.43M compared to total debt of $15.67M, creating a net cash position, although the debt-to-equity ratio is listed as N/A. While the debt level is low relative to cash, the negative equity implied by the P/E and price-to-book metrics suggests the balance sheet is structured around equity dilution rather than leverage. The current ratio is 2.01, which indicates a strong ability to meet short-term obligations with its liquid assets. Return on equity is N/A, while return on assets is -23.4%, revealing that the asset base is currently generating negative returns due to the heavy investment in development without corresponding commercial earnings.
Valuation Assessment
The trailing P/E ratio is N/A due to negative earnings, whereas the forward P/E is -58.74, a metric that is often used cautiously for loss-making companies. The difference between these metrics implies that the market is pricing in significant uncertainty regarding the trajectory of future earnings, as the forward multiple remains negative. The price-to-book ratio is -1.52, which indicates that the company is trading below its book value, a situation typical for firms where intangible assets like intellectual property are not fully captured on the balance sheet or where market sentiment is cautious. Additionally, the price-to-sales ratio is 3.77 and the EV/EBITDA is -0.78, suggesting that valuation is being driven primarily by revenue potential and sales growth prospects rather than current profitability or cash generation. The stock has traded between a 52-week high of $26.54 and a 52-week low of $5.20. The current price sits significantly below the 52-week high, reflecting a substantial correction from recent peaks, while the low point establishes a floor where the stock has found support over the last year. Beta is listed as N/A, meaning there is insufficient data to quantify the stock's volatility relative to the broader market, though the wide trading range between $5.20 and $26.54 suggests inherent high volatility typical of small-cap biotechnology stocks.
Growth & Income
Revenue growth year-over-year is -21.4%, while earnings growth is N/A due to the company's negative earnings position. The decline in revenue indicates a contraction in sales, which combined with negative earnings, implies that the company is currently in a phase where commercial performance is insufficient to cover its development and operational expenditures. Since the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%. This lack of dividend distribution means the company reinvests all available earnings or capital back into growth initiatives, such as advancing its lead products through clinical trials, rather than returning value to shareholders in the form of cash payouts. The overall growth and income profile presents a scenario of revenue contraction and negative earnings, where the primary value proposition relies entirely on the potential future success of its oncology pipeline rather than current profitability or income generation.